Phase IV clinical trial of 99Tcm-tetrofosmin injection: safety and efficiency for myocardial perfusion imaging

Shao-liang Chen
2008-01-01
Abstract:Objective A new myocardial perfusion imaging kit, 99Tcm-bis [bis (2-ethoxyethyl) phosphinol] ethane (tetrofosmin) was produced by Jiangsu Institute of Nuclear Medicine. The purpose of this study was to evaluate the safety and efficiency of this drug. Methods It was a random, double-blind, parallelism, and control experiment. After registration consent forms finished by the patients, stress (dipyridamole) and rest myocardial perfusion imaging were performed. The physical signs, including blood pressure, heart rate, rhythm of the heart, and breath before and after intravenous injection were be monitored within 4h. If any patient experienced to have any discomfort or any unfavourable sign, he (or she) would be sent to emergency room for further evaluation and (or) treatment. Results Totally 208 patients with coronary artery disease entered. Of the 208 volunteers, 100 belonged to study group (with the 99Tcm-tetrofosmin that was produced by Jiangsu Institute of Nuclear Medicine) and 108 belonged to control group [with the 99Tcm-methoxyisobutylisonitrile (MIBI) that was not produced by Jiangsu Institute of Nuclear Medicine]. No adverse event was noted among these 208 patients. Moreover, no statistical difference between diagnostic accuracy was noted in these two groups, or in imaging quality. Conclusion The phase IV clinical trial demonstrated that this new myocardial perfusion imaging kit was safe and had a comparable quality as compared with other commercial products.\r\n\r\nKey words: \r\nRadionuclide ventriculography;  99Tcm-tetrofosmin;  MIBI;  Clinical trials
What problem does this paper attempt to address?